Valion Bio Receives Unsolicited Acquisition Interest in Velocity Bioworks
Valion Bio received unsolicited acquisition inquiries from independent third parties concerning its wholly owned CDMO subsidiary, Velocity Bioworks, and is in preliminary discussions while evaluating strategic options. A potential sale could provide additional capital for Entolimod's ongoing development and other corporate priorities, while retaining production rights and continued manufacturing capabilities is a key priority. Valion has not committed to a sale or any other specific transaction and said discussi...
Key takeaways
Independent third parties submitted unsolicited acquisition inquiries concerning Velocity Bioworks.
Valion is in preliminary discussions with interested parties and is evaluating a range of strategic options, including a possible sale.
The strategic review is intended to support advancement of Entolimod and other pipeline assets, development of Velocity's commercial business, and evaluation of opportunities for the CDMO subsidiary.
Valion continues to operate Velocity and pursue new customer relationships.
Valion retained an unnamed nationally recognized investment banking firm as financial advisor to its Board.
A potential sale could provide additional capital, subject to its structure, while retaining production rights and securing manufacturing capabilities for Entolimod and potentially other pipeline assets remains a key priority.
Valion has not committed to a transaction, and there is no assurance discussions will result in a definitive agreement or completed transaction.
Key metrics
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open Investor relationsFollow VBIO in real time
Get material earnings, filing, IR, and earnings-call alerts by email.